|03-31-2009, 10:19 AM||#1|
Join Date: Sep 2004
Over comming myelin-mediated inhibition of oligodendrocyte precursor differentiation
Brain. 2009 Feb;132(Pt 2):465-81.
Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling.
Baer AS, Syed YA, Kang SU, Mitteregger D, Vig R, Ffrench-Constant C, Franklin RJ, Altmann F, Lubec G, Kotter MR.
Department of Neurosurgery, Medical University Vienna, Vienna, Austria.
Failure of oligodendrocyte precursor cell (OPC) differentiation contributes significantly to failed myelin sheath regeneration (remyelination) in chronic demyelinating diseases. Although the reasons for this failure are not completely understood, several lines of evidence point to factors present following demyelination that specifically inhibit differentiation of cells capable of generating remyelinating oligodendrocytes. We have previously demonstrated that myelin debris generated by demyelination inhibits remyelination by inhibiting OPC differentiation and that the inhibitory effects are associated with myelin proteins. In the present study, we narrow down the spectrum of potential protein candidates by proteomic analysis of inhibitory protein fractions prepared by CM and HighQ column chromatography followed by BN/SDS/SDS-PAGE gel separation using Nano-HPLC-ESI-Q-TOF mass spectrometry. We show that the inhibitory effects on OPC differentiation mediated by myelin are regulated by Fyn-RhoA-ROCK signalling as well as by modulation of protein kinase C (PKC) signalling. We demonstrate that pharmacological or siRNA-mediated inhibition of RhoA-ROCK-II and/or PKC signalling can induce OPC differentiation in the presence of myelin. Our results, which provide a mechanistic link between myelin, a mediator of OPC differentiation inhibition associated with demyelinating pathologies and specific signalling pathways amenable to pharmacological manipulation, are therefore of significant potential value for future strategies aimed at enhancing CNS remyelination.
“As the cast of villains in SCI is vast and collaborative, so too must be the chorus of hero's that rise to meet them” Ramer et al 2005
|Thread||Thread Starter||Forum||Replies||Last Post|
|Therapies for Spinal Cord Injury||Wise Young||Cure||9||03-30-2004 02:44 PM|
|Bettelli, et al. (2003). Myelin Oligodendrocyte Glycoprotein-specific T Cell Receptor Transgenic Mice Develop Spontaneous Autoimmune Optic Neuritis.||Wise Young||Multiple Sclerosis Research||0||05-07-2003 05:05 AM|
|McGee & Strittmatter (2003). The Nogo-66 receptor: focusing myelin inhibition of axon regeneration.||Wise Young||SCI (Animal) Research||0||04-13-2003 10:40 PM|
|Bruno, et al. (2002). Multiple sclerosis candidate autoantigens except myelin oligodendrocyte glycoprotein are transcribed in human thymus.||Wise Young||Multiple Sclerosis Research||1||03-08-2003 10:01 AM|
|LANCETÂ´S ARTICLE||KIM||Cure||2||10-04-2002 09:52 AM|